Elena Filipova, Elitsa Gotseva, Katya Uzunova, Velichka Pavlova, Silvia Hristova and Toni Vekov
Introduction: COVID-19, caused by the coronavirus SARS-CoV-2 has quickly spread around the world. Currently there is an active search for vaccines and therapeutics, including repurposing of well-known drugs. COVID-19 continues to be a challenge with only a few therapeutic and no chemoprophylactic interventions to combat the virus.
Methods: We aimed to review available data for the application of hydroxychloroquine (HCQ) as a chemoprophylactic agent for COVID-19, outline weakness of published trials and assess the objectivity of conclusions regarding the possible benefits of HCQ prophylaxis against the novel coronavirus disease.
Results: Our search turned 15 articles describing trials investigating the application of HCQ as a chemoprophylactic agent for COVID-19. Different cohorts of subjects were used, mainly health care workers exposed to coronavirus patients; people with rheumatic arthritis and systemic lupus erythematosus; cases of household transmission.
Conclusions: Trials investigating the potential of HCQ to be a prophylactic agent for SARS-CoV-2 have quite conflicting results. Further research is required in the form of large randomized trials with carefully considered methodological approach which will help avoid limitations making the potential results unreliable.
